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calculated by using the human capital approach. Costs were
discounted at 5%. Annual and lifetime direct and indirect costs,
in US dollars (USD), were determined on a per patient basis,
and were then projected to the overall Colombian type-2 dia-
betes mellitus population. RESULTS: The estimated annual
total cost of type 2 diabetes mellitus was $2.7 billion USD from
the societal perspective. From the ministry of health perspec-
tive, the annual estimated cost was $921 million USD. The
annual direct cost per patient was $288 USD, and the annual
indirect cost per patient was $559 USD The distribution of this
cost over the different model disease stages was as follows: dia-
betes treatment, 47%; cardiac and coronary disease, 24%;
stroke, 15%; retinopathy, 2%, nephropathy 3%; and amputa-
tion, 9%. Macrovascular complications comprised 86% of the
annual direct costs and 95% of the annual indirect costs of
type 2 diabetes mellitus. CONCLUSION: The economic burden
of type 2 diabetes mellitus in Columbia is comparable to results
for other countries. The developed model showed a logical
disease progression.
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OBJECTIVES: To analyze the clinical and economic impact of
adequate control of glycosylated hemoglobin (HbA1c) over the
chronic complications of Type-2 Diabetes mellitus. METHODS:
A Monte Carlo simulation was performed termed Diabetes Mel-
litus Model (DMM), previously validated, and published. The
inﬂuence parameter of DMM was (HbA1c) simulated for each
patient. A temporary horizon of ﬁve years was set. The design
compared two hypothetical groups of 1000 patients each, with
identical parameters. Group one included patients not respond-
ing to conventional treatment with insulin, who initiated with a
serum level of 9.1% of HbA1c the ﬁrst year and remained at this
value during the four following years. This HbA1c value corre-
sponds to the average level seen in the Mexican population when
initially treated (ﬁrst level of attention). Group two included
patients responding to intensive treatment with insulin, who
initiated with 9.1% HbA1c and reached an average value of
7.5% HbA1c. The cost of complications was calculated through
the estimation of the direct cost. RESULTS: There were 209.69
events in group one, and 160.44 events in group two, a difference
of 43.65. There were 7.01 more hypoglycemic events in the
group two. Group one had 17.01 more cases of clinical neuropa-
thy, with an estimated cost of €1715.51 per/event. For diabetic
foot syndrome there were 2.31 more in group one with a cost of
€5180.35 annually. The model projected more cases of microal-
buminuria, who without adequate treatment would progress to
advanced renal disease, and 1.61 more events of advanced renal
disease with an annual cost of €22,273.35. CONCLUSION: The
model results justify prevention measures in the ﬁrst level of
attention emphasizing in the strict metabolic control to reduce
the start of the micro-vascular damage of target organs; reducing
the demand of hospitalization, labor incapacities and use of
high-specialty medications which represent the highest costs of
the health system.
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OBJECTIVES: To estimate the impact of achieving the American
Diabetes Association (ADA) goal for glycemic control
(HbA1c < 7.0%) on long-term costs associated with managing
the complications of Type II diabetes. The ADA also sets goals
for blood pressure (systolic <130 mmHg and diastolic
<80 mmHg), lipids (LDL-C < 100 mg/dL, HDL-C > 40 mg/dL
men, 50 mg/dL women, triglycerides <150 mg/dL). There is evi-
dence many do not achieve these targets, and have sub-optimal
control of cardiovascular risk factors. METHODS: A discrete
event simulation of the long-term economic impact of complica-
tions (cardiovascular and microvascular) for patients with Type
II diabetes was developed. Model parameters and risk functions
for complications were based on the UKPDS, Saskatchewan
health database analyses, and literature. A cohort is created by
reading in proﬁles including age (mean 59.3 years), gender (57%
male), blood pressure (mean SBP 132 mmHg), and lipids (mean
total cholesterols 5.32 mmol/L) extracted from patients with
Type II diabetes diagnosed for less than 5 years in NHANES
2001–2002. Two cohorts were simulated with HbA1c less than
and above 7%. One hundred replications of 1000 patients were
run over 20 years. Direct medical costs reported in 2004USD ($)
include hospital admission, outpatient, and routine care.
RESULTS: The average cost per patient who were above goal
(mean baseline HbA1c 9%) over 20 years was predicted at
$38,137 compared to $26,882 for patients at goal (mean base-
line HbA1c 6%). Complication rates were lower in patients at
goal: 29% fewer cardiovascular and 36% fewer microvascular
complications. Average life expectancy was 13.49 years, 0.44
years longer than those not at goal. Although over the ﬁrst 10
years, cardiovascular related costs were majority of the total
costs accrued, microvascular complications developed later in the
course of diabetes and their costs became majority over 20 years.
CONCLUSION: Patients achieving the recommended glycemic
goals are expected to substantially decrease complication costs
and complications rates.
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OBJECTIVES: To quantify the true cost of insulin prescribing in
type 2 diabetes (T2D) including insulin and insulin ancillary
items. Few data on annual insulin cost exist. Insulin is difﬁcult to
cost due to the array of insulins, wide dosing ranges, prn usage
following self testing and usage of insulin ancillaries e.g. lancets,
needles and testing strips. METHODS: Prescribing data were
collected from a longitudinal real patient database (the IMS UK
Disease Analyzer database) showing prescribing data of 650 GPs
within 130 practices across the UK providing access to 95 m
prescriptions. Costs were then assigned to the data. The popula-
tion was existing T2D patients with incidence of insulin usage,
deﬁned as those patients: Prescribed insulin with a prescription
for any oral antidiabetic drug prior to insulin and aged >40 y at
ﬁrst record of diabetes; With Read code of T2D (could include
patients <40 y); additionally incident on insulin after January 1,
2002. Costs of insulin prescriptions and ancillaries were drawn
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from the database sourced from the UK drug tariff, BNF and
MIMS (with appropriate assumptions where quantities were
unclear). RESULTS: In total, 3581 patients met the inclusion
criteria. The average dose of insulin in T2D patients within the
study was 36IU/day at 12 months. The average yearly cost was
384 for insulin alone and ancillary item cost reached 223
increasing total annual cost of insulin and equipment to 607.
CONCLUSION: Although clinically appropriate for some T2D
patients, insulin is expensive, particularly when ancillaries are
considered.This database study was a straightforward way of
identifying and analysing not only drug costs but ‘hidden’ costs
of insulin ancillaries.This analysis only takes account of insulin
and ancillary costs and does not account for visits to health care
professionals. Initiation of insulin is often accompanied by extra
visits to health care professionals, which would further increase
costs.
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OBJECTIVES: The primary objective of the INSTIGATE study is
to assess the direct costs of care for type 2 diabetes in the 6
months before and after insulin initiation. This abstract presents
data for patients enrolled in Germany and UK. METHODS:
INSTIGATE is an ongoing prospective European observational
study investigating patients with type 2 diabetes who have initi-
ated insulin during usual care. The direct costs of diabetes care
over the 6 months prior to and after insulin initiation were
calculated by collecting data on individual resource use and
assigning local unit costs. Data collected included; number of
consultations with health care professionals, details of oral anti-
diabetic medications and insulins, hospitalisations for diabetes
care or complications, and frequency of blood glucose monitor-
ing. RESULTS: Five hundred and nine patients were enrolled in
Germany and UK, and 6 month follow-up data was collected
from 457 patients. In Germany the median costs per patient for
diabetes care in the 6 months prior to and after insulin initiation
were 406€ and 893€ respectively. In the UK the median costs per
patient for diabetes care in the 6 months prior to and after insulin
initiation were 596€ and 707€ respectively (2006 costs). CON-
CLUSION: For German and UK patients included in this study
the median cost of care for diabetes in the 6 months following
insulin initiation is higher than in the 6 months prior to insulin
initiation. Differences in types of resource use pre and post
insulin initiation have been observed and further analysis is
underway to investigate how these differences, and the cost of
insulin, are impacting costs of care. Outcomes following insulin
initiation will also be investigated.
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OBJECTIVES: In Spain there are several pharmaceutical prod-
ucts for the treatment of type 2 diabetes mellitus (DM2), with
different proﬁles which implies alternative patterns of adminis-
tration. A comparative study comparing annual costs linked to
the treatment with Glargine insulin (GI) and Detemir insulin (DI)
has been performed with the Spanish National Health System
perspective. METHODS: Clinical data related with each treat-
ment derives, mainly, from a study performed by Rosenstock
et.al (2006): a 52-week open-label, parallel, multinational trial,
which compares efﬁcacy and safety of GI and DI. This trial has
shown that patients treated with GI required less dairy dose of
insulin and suffer from less severe hypoglycaemia than those
patients treated with DI. Data about other use of related medical
resources (consumption of needles and blood glucose tests,
and management of major hypoglycaemic episodes) has been
obtained from Spanish published literature. Costs calculations
refer to year 2007 and have been derived from Spanish databases
and published tariffs. RESULTS: Patients treated with ID require
65% more dose than those treated with GI, and suffer more
major hypoglycaemic events. In patients with DM2 management
with GI has lower total costs than DI, which allows savings up to
534.96€ per patient-year. Savings are related with costs of total
insulin, needles and blood glucose tests and also medical man-
agement required in case of major hypoglycaemic events. CON-
CLUSION: For patients with DM2 treatment with GI is an
efﬁcacious and safe therapeutic option compared with DI,
because GI is associated with lower annual total costs, and
allows saving up to 534.96€ per patient-year i.e. a 34% saving
per patient-year.
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OBJECTIVES: Pregnant women with diabetes report high rates
of neonatal mortality and morbidity. The costs of resulting inter-
ventions are potentially substantial. This study investigated
health outcomes and inpatient costs in pregnant women with
type 1 diabetes. METHODS: This analysis utilised a cohort of
302 pregnant women with type 1 diabetes, enrolled before 10
weeks gestation, with HbA1C  8% at conﬁrmation of preg-
nancy and for whom birth outcome was known. Subjects were
participating in a randomised study of basal-bolus insulin regi-
mens, with doses titrated in line with the American Diabetes
Association (ADA) guidelines. Outcomes recorded included
major maternal hypoglycaemia, neonatal hypoglycaemia, obstet-
ric complications, congenital malformations, foetal loss, birth
before 37 weeks gestation, birth weight >4000 g, and other
adverse events if life threatening or requiring hospitalisation.
Resulting inpatient costs were estimated from the perspective of
the UK National Health Service. RESULTS: The percentage of
subjects reporting major maternal hypoglycaemia was 29%,
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